A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a dedicated discovery and clinical-stage biopharmaceutical company advancing the next generation of gene and cell therapies with the overall goal of improving outcomes for patients with significant unmet medical needs. We are leveraging our proprietary technology platforms to develop product candidates designed to target urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. We have developed an extensive pipeline of therapies across multiple indications. We believe that our array of technology platforms uniquely positions us among other biotechnology companies to advance precision medicine. Precision medicine is the practice of therapeutic product development that takes into account specific genetic variations within populations impacted by a disease to design targeted therapies to improve outcomes for a disease or patient population.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | - | 27M | - | - |
| Net Income | 0 | -126M | -96M | 28M | -92M | -171M |
| EPS | $0.00 | $-0.47 | $-0.39 | $0.14 | $-0.47 | $-1.02 |
| Free Cash Flow | 0 | -77M | -68M | -70M | -63M | -85M |
| ROIC | - | 10.8% | -80.9% | 21.9% | -32.1% | -71.4% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 2.04 | 0.00 | 0.68 | 1.68 | 2.56 |
| Dividends/Share | $0.00 | $0.00 | $0.00 | - | - | - |
| Operating Income | 0 | 8.5M | -100M | 37M | -85M | -163M |
| Operating Margin | 0.0% | - | - | 136.2% | - | - |
| ROE | 0.0% | -160.8% | -80.9% | 24.2% | -105.6% | -245.6% |
| Shares Outstanding | 269M | 269M | 246M | 202M | 196M | 167M |
PRECIGEN, INC. passes 1 of 9 quality checks, indicating weak fundamentals.
At current prices, the estimated annualized return to fair value is +16.0%.
PRECIGEN, INC. (PGEN) has a 5-year average return on invested capital (ROIC) of -30.4%. This is below average and may indicate limited pricing power.
PRECIGEN, INC. (PGEN) has a market capitalization of $1.1B. It is classified as a small-cap stock.
PRECIGEN, INC. (PGEN) does not currently pay a regular dividend.
PRECIGEN, INC. (PGEN) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
PRECIGEN, INC. (PGEN) generated $-77 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
PRECIGEN, INC. (PGEN) has a debt-to-equity ratio of 2.04. This indicates higher leverage, which may increase financial risk.
PRECIGEN, INC. (PGEN) reported earnings per share (EPS) of $-0.47 in its most recent fiscal year.
PRECIGEN, INC. (PGEN) has a return on equity (ROE) of -160.8%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 14 years of financial data for PRECIGEN, INC. (PGEN), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
PRECIGEN, INC. (PGEN) has a book value per share of $0.14, based on its most recent annual SEC filing.